Depemokimab not checked

GSK · GSK3511294

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
8 active
18 in total · 9 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Depemokimab as a sterile liquid formulation will be administered.”In the company’s words, NCT06961214 on ClinicalTrials.gov
Tested for
Asthma (3 trials), Pulmonary Disease, Chronic Obstructive (3 trials), Nasal Polyps, Hypereosinophilic Syndrome
Main trialPhase 4
“This study will evaluate the efficacy and safety of depemokimab (GSK3511294) without concomitant use of Intranasal corticosteroids (INCS) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).”In the company’s words, NCT07701967 on ClinicalTrials.gov
Other names
GSK3511294

Other drugs for Asthma

All 58 drugs for Asthma

Coming up8

Changes3

Last 90 days

Trials18

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 28 Jun 2027 Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Phase 3Recruiting 1 Mar 2027 A Study of Depemokimab in Participants of 6 to 11 Years of Age
Phase 3Active, not recruiting 29 Oct 2027 Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Phase 3Recruiting 5 Jan 2028 Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Phase 3Recruiting 13 Dec 2028 Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Phase 3Recruiting 13 Dec 2028 Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
Phase 3Recruiting 2 Apr 2029 eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Phase 3Recruiting 23 Sep 2030 A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
Phase 3Completed 21 Nov 2023 Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
Phase 3Completed 11 Apr 2024 A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
Phase 3Completed 12 Jul 2024 Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)
Phase 3Completed 30 Jul 2024 Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
Phase 3Completed 19 May 2025 An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
Phase 3Completed 14 Sep 2025 A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
Phase 3Completed 6 Oct 2026 Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Phase 1Completed 31 Jul 2019 First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma
Phase 1Completed 23 Dec 2022 Study of GSK3511294 in Healthy Chinese Participants
Phase 1Completed 23 Oct 2023 A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Depemokimab

Following is part of Solo: you see every change to Depemokimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in